We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lucira Health Inc (LHDX) USD0.001

Sell:$2.00 Buy:$2.04 Change: No change
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Change: No change
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lucira Health, Inc. is medical technology company. The Company is focused on the development and commercialization of transformative and infectious disease test kits. The Company has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. It has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.

Contact details

1412 62nd Street
United States
+1 (814) 5741546

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$78.14 million
Shares in issue:
39.83 million
Health Care Equipment
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Erik Engelson
    President, Chief Executive Officer, Director
  • Daniel George
    Chief Financial Officer, Treasurer
  • Hansgregory Hartmann
    Chief Operating Officer
  • Ghazi Kashmolah
    Chief Quality Officer and Executive Vice President Regulatory Affairs
  • Kelly Lewis Brezoczky
    Executive Vice President - Commercialization, Regulatory, Clinical and Business Development
  • Debkishore Mitra
    Chief Technology Officer
  • Tamanna Prashar
    Vice President - Global Supply Chain, Operations and Quality

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.